Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment

J Clin Psychiatry. 2002;63 Suppl 9:25-9.

Abstract

The atypical antipsychotic drugs are a major advance in the treatment of psychosis in spite of concerns about metabolic and cardiovascular side effects that affect morbidity and mortality. Concerns about weight gain, hypoglycemia, diabetes, and increases in lipids as well as sudden death due to torsades de pointes and other cardiovascular events can temper enthusiasm about the atypical antipsychotics. The challenge for the clinician is to weigh the benefits and risks for each drug for each patient and develop a treatment plan with the individual patient in mind. This article discusses both risks and benefits of antipsychotic treatment and presents a treatment algorithm to aid the clinician in choosing medications for the psychotic patient.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use*
  • Body Weight / drug effects
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / epidemiology
  • Cognition Disorders / drug therapy
  • Comorbidity
  • Decision Trees
  • Depressive Disorder / drug therapy
  • Humans
  • Hyperlipidemias / chemically induced
  • Hyperlipidemias / epidemiology
  • Hypertension / chemically induced
  • Hypertension / epidemiology
  • Practice Patterns, Physicians'
  • Psychotic Disorders / drug therapy*
  • Risk Assessment
  • Risk Factors
  • Schizophrenia / drug therapy
  • Torsades de Pointes / chemically induced
  • Torsades de Pointes / epidemiology

Substances

  • Antipsychotic Agents